The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model

<div>(a) Change percentage of total atheroma volume (TAV) and percentage atheroma volume (PAV) in OLIVUS study in 14-months follow-up. Olmesartan significantly demonstrates a greater change in both parameters. (b) PERSPECTIVE study demonstrated no significant difference in PAV change between the perindopril and control group.</div>

International Journal of Vascular Medicine

fig3

Figure 3

Figure 3: The Role of Angiotensin Antagonism in Coronary Plaque Regression: Insights from the Glagovian Model 